Evidence map›Paper›PMID 40943317›Full record

Observational studyInternational journal of molecular sciences2025

The OvarianTag™ Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer.

Letícia da Conceição Braga, Laurence Rodrigues do Amaral, Pedro Henrique Villar Delfino, Nara Rosana Andrade, Paulo Guilherme de Oliveira Salles, Agnaldo Lopes da Silva Filho, Pedro Luiz Lima Bertarini, Ana Paula Álvares da Silva Ramos, Matheus de Souza Gomes, Luciana Maria Silva Lopes

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Letícia da Conceição BragaOncotag Desenvolvimento de Produtos e Servicos Para Saúde HumanaRua Tiradentes, 2689, Sala 102, Industrial, Contagem 32230-020, MG, Brazil.ORCID 0000-0002-6181-9410
Laurence Rodrigues do AmaralUniversidade Federal de Uberlândia, Campus Patos de Minas, Patos de Minas 38702-178, MG, Brazil.ORCID 0000-0003-4681-5451
Pedro Henrique Villar DelfinoOncotag Desenvolvimento de Produtos e Servicos Para Saúde HumanaRua Tiradentes, 2689, Sala 102, Industrial, Contagem 32230-020, MG, Brazil.
Nara Rosana AndradeOncotag Desenvolvimento de Produtos e Servicos Para Saúde HumanaRua Tiradentes, 2689, Sala 102, Industrial, Contagem 32230-020, MG, Brazil.
Paulo Guilherme de Oliveira SallesLaboratório de Pesquisa Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte 30380-420, MG, Brazil.
Agnaldo Lopes da Silva FilhoDepartamento de Ginecologia e Obstetrícia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0002-8486-7861
Pedro Luiz Lima BertariniUniversidade Federal de Uberlândia, Campus Patos de Minas, Patos de Minas 38702-178, MG, Brazil.ORCID 0000-0003-1816-564X
Ana Paula Álvares da Silva RamosOncotag Desenvolvimento de Produtos e Servicos Para Saúde HumanaRua Tiradentes, 2689, Sala 102, Industrial, Contagem 32230-020, MG, Brazil.
Matheus de Souza GomesUniversidade Federal de Uberlândia, Campus Patos de Minas, Patos de Minas 38702-178, MG, Brazil.
Luciana Maria Silva LopesServiço de Biologia Celular, Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias, Belo Horizonte 30510-010, MG, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02564-22
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, often diagnosed at an advanced stage due to its asymptomatic progression. The high recurrence rate and development of platinum-based chemotherapy resistance contribute to its poor prognosis. Despite advancements in molecular profiling, predictive biomarkers for chemotherapy response and recurrence risk remain limited. In this study, we developed OvarianTag™, a biomarker panel integrating apoptosis and necroptosis pathways, to predict chemotherapy benefit and disease progression in EOC patients. This observational study was conducted in two phases. In the first phase, 45 patients were recruited, and RNA was extracted from fresh ovarian tissues (normal, benign, and malignant). qRT-PCR was performed to assess the relative expression of genes involved in apoptosis and necroptosis-regulated cell death pathways. Machine learning algorithms were applied to identify the relevant prognostic markers, leading to the development of OvarianTag™. In the second phase, 55 additional EOC patients were included, and their formalin-fixed, paraffin-embedded (FFPE) tumor samples were analyzed using qRT-PCR. The classifier algorithm incorporated hierarchical clustering to stratify patients based on gene expression profiles. Significant differences in

Indexed as

Antineoplastic AgentsBiomarkers, TumorCarcinoma, Ovarian EpithelialCisplatinOvarian NeoplasmsAdultAgedApoptosisClinical Decision-MakingFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisAntineoplastic AgentsBiomarkers, TumorCisplatinbiomarkersepithelial ovarian cancerextrinsic apoptosis cell signalingOvarianTag™platinum-resistance

Identifiers

PMID40943317
PMCPMC12428831

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.